Bon Natural Life (BON) Competitors $1.41 -0.01 (-0.46%) Closing price 03:51 PM EasternExtended Trading$1.42 +0.01 (+0.35%) As of 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock BON vs. SLRX, PTPI, PBLA, HEPA, BPTSY, ORGS, VIRX, TRVN, MYMD, and VINCShould you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include Salarius Pharmaceuticals (SLRX), Petros Pharmaceuticals (PTPI), Panbela Therapeutics (PBLA), Hepion Pharmaceuticals (HEPA), Biophytis (BPTSY), Orgenesis (ORGS), Viracta Therapeutics (VIRX), Trevena (TRVN), MyMD Pharmaceuticals (MYMD), and Vincerx Pharma (VINC). These companies are all part of the "pharmaceutical products" industry. Bon Natural Life vs. Its Competitors Salarius Pharmaceuticals Petros Pharmaceuticals Panbela Therapeutics Hepion Pharmaceuticals Biophytis Orgenesis Viracta Therapeutics Trevena MyMD Pharmaceuticals Vincerx Pharma Bon Natural Life (NYSE:BON) and Salarius Pharmaceuticals (NASDAQ:SLRX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk. Which has better valuation & earnings, BON or SLRX? Bon Natural Life has higher revenue and earnings than Salarius Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBon Natural Life$23.84M0.01$400KN/AN/ASalarius PharmaceuticalsN/AN/A-$5.58M-$43.48-0.13 Does the media favor BON or SLRX? In the previous week, Salarius Pharmaceuticals had 3 more articles in the media than Bon Natural Life. MarketBeat recorded 3 mentions for Salarius Pharmaceuticals and 0 mentions for Bon Natural Life. Salarius Pharmaceuticals' average media sentiment score of 0.63 beat Bon Natural Life's score of 0.00 indicating that Salarius Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Bon Natural Life Neutral Salarius Pharmaceuticals Positive Which has more risk & volatility, BON or SLRX? Bon Natural Life has a beta of -0.47, suggesting that its share price is 147% less volatile than the S&P 500. Comparatively, Salarius Pharmaceuticals has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Is BON or SLRX more profitable? Bon Natural Life's return on equity of 0.00% beat Salarius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Bon Natural LifeN/A N/A N/A Salarius Pharmaceuticals N/A -556.47%-192.35% Do institutionals & insiders have more ownership in BON or SLRX? 0.6% of Bon Natural Life shares are owned by institutional investors. Comparatively, 11.9% of Salarius Pharmaceuticals shares are owned by institutional investors. 26.5% of Bon Natural Life shares are owned by insiders. Comparatively, 1.2% of Salarius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryBon Natural Life beats Salarius Pharmaceuticals on 5 of the 9 factors compared between the two stocks. Get Bon Natural Life News Delivered to You Automatically Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BON vs. The Competition Export to ExcelMetricBon Natural LifeMedicinals & botanicals IndustryDiscretionary SectorNYSE ExchangeMarket Cap$235K$3.52B$8.45B$21.26BDividend YieldN/AN/A3.03%3.51%P/E RatioN/A9.0518.1829.31Price / Sales0.0167.625.4669.12Price / Cash0.785.6217.1523.86Price / Book0.041.214.785.36Net Income$400K$17.44M$227.91M$996.52M7 Day Performance2.17%8.99%1.00%0.44%1 Month Performance2.92%15.09%15.59%3.55%1 Year Performance-96.87%16.59%50.76%12.14% Bon Natural Life Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BONBon Natural LifeN/A$1.41-0.5%N/A-96.9%$235K$23.84M0.00100Gap DownSLRXSalarius Pharmaceuticals0.1451 of 5 stars$6.47-3.2%N/A-76.6%$919KN/A-2.2320Stock SplitPTPIPetros PharmaceuticalsN/A$0.03-2.3%N/A-99.7%$913K$5.11M-0.0120PBLAPanbela Therapeutics0.2723 of 5 stars$0.16flatN/A-56.5%$767KN/A0.006Positive NewsHEPAHepion Pharmaceuticals0.4963 of 5 stars$0.06+2.9%N/A-99.8%$741KN/A-0.0120Gap DownBPTSYBiophytisN/A$2.00+10.8%N/AN/A$702KN/A0.0030Positive NewsGap UpORGSOrgenesis1.7581 of 5 stars$0.14+538.6%N/AN/A$674K$662K0.00150Negative NewsGap UpVIRXViracta Therapeutics1.6808 of 5 stars$0.01flat$1.13+11,403.1%N/A$389KN/A-0.0120TRVNTrevena1.2465 of 5 stars$0.28-1.8%$5.00+1,718.2%-100.0%$264K$443K-0.0140MYMDMyMD PharmaceuticalsN/A$0.10+0.8%N/A-95.6%$241KN/A0.006High Trading VolumeVINCVincerx Pharma2.4959 of 5 stars$0.04-6.7%$40.00+110,703.3%-99.7%$189KN/A0.0060Gap Up Related Companies and Tools Related Companies Salarius Pharmaceuticals Competitors Petros Pharmaceuticals Competitors Panbela Therapeutics Competitors Hepion Pharmaceuticals Competitors Biophytis Competitors Orgenesis Competitors Viracta Therapeutics Competitors Trevena Competitors MyMD Pharmaceuticals Competitors Vincerx Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BON) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bon Natural Life Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bon Natural Life With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access